236 related articles for article (PubMed ID: 17320674)
41. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
42. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):293-9. PubMed ID: 12909246
[TBL] [Abstract][Full Text] [Related]
43. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
44. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
[TBL] [Abstract][Full Text] [Related]
45. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
46. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
[TBL] [Abstract][Full Text] [Related]
47. Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer.
Peng LC; Mian OY; Lakshminarayanan P; Huang P; Bae HJ; Robertson S; Habtu T; Narang A; Agarwal S; Greco S; Tran P; McNutt T; DeWeese TL; Song DY
Urology; 2020 Jan; 135():111-116. PubMed ID: 31454660
[TBL] [Abstract][Full Text] [Related]
48. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy.
Tsui G; Gillan C; Pond G; Catton C; Crook J
Cancer J; 2005; 11(2):122-32. PubMed ID: 15969987
[TBL] [Abstract][Full Text] [Related]
49. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma.
Wehle MJ; Lisson SW; Buskirk SJ; Broderick GA; Young PR; Igel TC
Mayo Clin Proc; 2004 Mar; 79(3):314-7. PubMed ID: 15008604
[TBL] [Abstract][Full Text] [Related]
50. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
51. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
52. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
[TBL] [Abstract][Full Text] [Related]
53. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
54. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results.
Wilder RB; Chou RH; Ryu JK; Stern RL; Wong MS; Ji M; Roach M; White RD
Am J Clin Oncol; 2000 Aug; 23(4):330-3. PubMed ID: 10955856
[TBL] [Abstract][Full Text] [Related]
55. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
Ellis RJ; Zhou H; Kaminsky DA; Fu P; Kim EY; Sodee DB; Colussi V; Spirnak JP; Whalen CC; Resnick MI
Brachytherapy; 2007; 6(2):149-56. PubMed ID: 17434109
[TBL] [Abstract][Full Text] [Related]
56. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
57. Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
Okihara K; Yorozu A; Saito S; Tanaka N; Koga H; Higashide S; Kikuchi T; Nakano M
Int J Urol; 2017 Jul; 24(7):518-524. PubMed ID: 28455847
[TBL] [Abstract][Full Text] [Related]
58. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
[TBL] [Abstract][Full Text] [Related]
59. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection.
Wallner K; Lee H; Wasserman S; Dattoli M
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):565-9. PubMed ID: 9112454
[TBL] [Abstract][Full Text] [Related]
60. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
